Urologia

Estudo randomizado | Vigilância ativa com enzalutamida em monoterapia vs. vigilância ativa isolada em pacientes com risco baixo ou intermediário de câncer de próstata localizado.

22 Jun, 2022 | 20:57h

Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer – JAMA Oncology

Comentário convidado: To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence – JAMA Oncology (gratuito por tempo limitado)

Vídeo criticando o artigo: ENACT trial | A Study That Makes Pharma Rich and Patients’ Poor | I break it down – by Vinay Prasad

 

Comentários no Twitter

55% fatigue and 36% gynecomastia. In AS patients.

Why do we keep trying to escalate when the data CLEARLY say we should continue to de-escalate? https://t.co/LY1kD0jN65

— Chris Barbieri (@Chris_Barbieri1) June 17, 2022

The phase 2, open-label ENACT trial compares the efficacy & safety of enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized #prostatecancer. https://t.co/q9FrL14em1 #PCSM #GUCSM

— JAMA Oncology (@JAMAOnc) June 16, 2022

 

---

Estudo de braço único fase 2B | Terapia focal centrada em ultrassom e guiada por ressonância magnética para pacientes com câncer de próstata de risco intermediário.

21 Jun, 2022 | 12:35h

MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comunicado de imprensa: High-intensity focused ultrasound (HIFU) can control prostate cancer with fewer side effects – Memorial Sloan Kettering Cancer Center

 

Comentário no Twitter

In single-arm phase IIb trial of MRI-guided focused ultrasound therapy in 101 men with primary, group 2‒3 intermediate-risk untreated prostate adenocarcinomas, 88% had no evidence of group ≥2 prostate cancer in the treated area at 2 years: https://t.co/xLpqfFm8Ds #PCSM

— NatureRevClinOncol (@NatRevClinOncol) June 16, 2022

 

---

Resultados de longo prazo de estudo randomizado | Radioterapia prostática para homens com câncer de próstata metastático.

16 Jun, 2022 | 13:37h

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial – PLOS Medicine

---

M-A | Eventos cardiovasculares adversos e mortalidade em homens durante o tratamento com testosterona.

16 Jun, 2022 | 13:34h

Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis – The Lancet Health Longevity

Comentário convidado: Testosterone: therapeutic or toxic for the cardiovascular health of men? – The Lancet Health Longevity

---

Novo estudo associa a ingestão de laticínios com maior risco de câncer de próstata.

16 Jun, 2022 | 13:29h

Comunicado de imprensa: New study associates intake of dairy milk with greater risk of prostate cancer – Loma Linda University Adventist Health Sciences Center

Estudo original: Dairy foods, calcium intakes, and risk of incident prostate cancer in Adventist Health Study–2 – American Journal of Clinical Nutrition (link para o resumo – $ para o texto completo)

---

DNA cirulante de tumor como biomarcador em pacientes com tumor de Wilms estágios III e IV.

14 Jun, 2022 | 13:33h

Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children’s Oncology Group Trial, AREN0533 – Journal of Clinical Oncology

Comentário: Analysis of Circulating Tumor DNA as a Biomarker in Stage III and IV Wilms Tumor – The ASCO Post

---

Estudo randomizado | Efeito da dexmedetomidina perioperatória sobre a função tardia do enxerto após transplante de rim doado após morte cardíaca.

14 Jun, 2022 | 12:51h

Effect of Perioperative Dexmedetomidine on Delayed Graft Function Following a Donation-After-Cardiac-Death Kidney Transplant: A Randomized Clinical Trial – JAMA Network Open

 

Comentário no Twitter

In this RCT, 24-hour dexmedetomidine infusion, started immediately after induction of & in addition to standard anesthesia, reduced the incidence of delayed graft function vs placebo, following a donation-after-cardiac-death kidney transplantation. https://t.co/cmX1IEZdVX

— JAMA Network Open (@JAMANetworkOpen) June 3, 2022

 

---

Diretriz | Avaliação e manejo médico do paciente com cálculo renal.

6 Jun, 2022 | 11:26h

Update – 2022 Canadian Urological Association guideline: Evaluation and medical management of the kidney stone patient – Canadian Urological Association Journal

---

Diretrizes de prática clínica para câncer peniano.

6 Jun, 2022 | 11:23h

Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological Association – International Journal of Urology

---

Estudo de coorte | O uso de inibidores da 5-alfa-redutase para hiperplasia prostática benigna não está associado com mortalidade aumentada no câncer de próstata.

2 Jun, 2022 | 13:34h

Comunicado de imprensa: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer – Karolinska Institute

Estudo original: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA Oncology (link para o resumo – $ para o texto completo)

Entrevista com os autores: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA

Comentário: Large study finds no increased risk for prostate cancer death with 5-ARI use – medwire News

 

Comentário no Twitter

This large population-based cohort study found that men treated with 5α-reductase inhibitors had no increased risk of dying from #prostatecancer, on the contrary indicating a decreased risk with longer treatment duration. https://t.co/y8HlpthNI9 #PCSM #GUCSM

— JAMA Oncology (@JAMAOnc) May 19, 2022

 

---